TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00096720
Drug: levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03709420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule to match active drug
Study: NCT03709420
Drug: FOR-6219
Normalized name: Gas for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOR-6219 capsule
Study: NCT01646437
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01712711
Drug: H.pylori eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
Study: NCT03857256
Drug: CP105F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural Health Product
Study: NCT03857256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet manufactured to mimic the CP105F beta-glucan
Study: NCT02541760
Drug: Monteleukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml monteleukast daily for one month
Study: NCT02077569
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
Study: NCT02472769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water
Study: NCT06448962
Drug: AD-2021
Normalized name: Fluad 2020-2021
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT06448962
Drug: AD-2022
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT06448962
Drug: AD-2021 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT06448962
Drug: AD-2022 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT04084496
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study: NCT04681027
Drug: Oxymorphone hydrochloride (HCl)
Normalized name: Oxymorphone Hydrochloride
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid
Study: NCT03872570
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT00690118
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, 18 months
Study: NCT01493622
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
Study: NCT01493622
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
Study: NCT03143023
Drug: arginine toothpaste
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acid neutralizer toothpaste
Study: NCT04243278
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo PO for 6 months
Study: NCT00352118
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous continuously on days 1-4.
Study: NCT01743625
Drug: COV155
Approvals — FDA: no, EMA: no, PMDA: no
Description: COV155 tablets
Study: NCT01743625
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02862782
Drug: hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)
Normalized name: ZOSTER VACCINE LIVE (OKA/MERCK)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01551212
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.
Study: NCT01767909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
Study: NCT00108446
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00190034
Drug: N-Acetylcysteine 600mg/tab
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02308046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03218241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous to mimic PRT064445
Study: NCT02471833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.
Study: NCT02850211
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
Study: NCT02850211
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
Study: NCT00002844
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily intravenous infusions of cyclophosphamide for two days,
Study: NCT01171105
Drug: AZD5213
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution, multiple ascending doses
Study: NCT01171105
Drug: Placebo to AZD5213
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02392780
Drug: Calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
Study: NCT02598453
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
Study: NCT00618293
Drug: Haemate HS
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of Haemate (dosage dependent on body weight)
Study: NCT00296244
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
Study: NCT04079803
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablet
Study: NCT00296244
Drug: Enteric-coated Mycophenolic acid (EC-MPA)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
Study: NCT00158899
Drug: GW501516 oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00070434
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825mg/m2 BID, PO, daily
Study: NCT03353350
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02254525
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.
Study: NCT00070434
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus + IV for 46 hrs on Day 1
Study: NCT00070434
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 IV 2 hour infusion on Day 1
Study: NCT00070434
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg TID, PO daily
Study: NCT02678117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01381497
Drug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)
Normalized name: sumatriptan and naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an observational study and patients were prescribed this medication before study start
Study: NCT00052559
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04283331
Drug: Proparacaine Ophthalmic
Normalized name: proparacaine ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
Study: NCT01381497
Drug: Triptan monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
Study: NCT03492996
Drug: LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a \[14C\]-LCB01-0371-tracer dose to healthy subjects
Study: NCT01838876
Drug: Antidepressant Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
Study: NCT00110708
Drug: Oralgam (human immunoglobulin)
Normalized name: immunoglobulin A, human
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03006874
Drug: CJ-12420 100mg QD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
Study: NCT03006874
Drug: CJ-12420 50mg QD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
Study: NCT00628264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
Study: NCT01866917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00565682
Drug: etoricoxib 120 mg
Normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg, tablet, orally, OD
Study: NCT00259103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01545336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg tablet to be taken 1 time daily
Study: NCT01258049
Drug: Artemether Sublingual Spray
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
Study: NCT04297592
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg oral tablet, 2 times daily for 7 days
Study: NCT06696807
Drug: glucocorticosteroids and/or intravenous immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day
Study: NCT02218008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study: NCT04323735
Drug: Culturelle 10 Billion CFU Capsule
Normalized name: Culturelle 10 Billion CFU Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group.
Study: NCT00666809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID p.o. for 12 weeks + 4 weeks follow-up
Study: NCT00357851
Drug: Aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03178539
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: non steroidal anti-inflammatory drug
Study: NCT03178539
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non steroidal anti-inflammatory drug
Study: NCT01722110
Drug: Indomethacin Extended-Release Capsules USP 75 mg
Normalized name: indomethacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg tablet once a day
Study: NCT00354029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: isotonic saline
Study: NCT02360345
Drug: ONX-0801
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01951716
Drug: Graded Glucose Infusion with Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Study: NCT01951716
Drug: Graded Glucose Infusion with GIP Alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Study: NCT01951716
Drug: Graded Glucose Infusion with xenin-25 alone
Normalized name: glucose 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Study: NCT02389400
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single Group Assignment
Study: NCT01133951
Drug: OAC triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
Study: NCT01133951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
Study: NCT02675868
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
Study: NCT02675868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% infusion
Study: NCT01951716
Drug: Graded Glucose Infusion with GIP plus xenin-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Study: NCT01951716
Drug: Meal Tolerance Test with Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes.
Study: NCT05269810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets b.i.d for 8 weeks
Study: NCT02839642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00632762
Drug: mantadix
Normalized name: chlorcyclizine hydrochloride / hydrocortisone acetate Topical Cream [Mantadil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
Study: NCT01951716
Drug: Meal Tolerance Test with xenin-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes.
Study: NCT03738241
Drug: AS03
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 oil-in-water emulsion-based adjuvant system containing DL-alpha-tocopherol, squalene, polysorbate 80, and a buffer.
Study: NCT01440374
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
Study: NCT02788656
Drug: Angiotensin-Converting Enzyme Inhibitor
Normalized name: Angiotensin-converting enzyme inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
Study: NCT01537653
Drug: SAR231893 (REGN668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
Study: NCT01537653
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
Study: NCT05108051
Drug: ZSP1273
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1273 tablets 600mg administered orally once daily
Study: NCT02607813
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological: PDR001 anti-PD1 antibody
Study: NCT02261415
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
Study: NCT04261920
Drug: Huangqi Guizhi Wuwu decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).
Study: NCT03454243
Drug: RXDX-106
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
Study: NCT03667326
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule, PO
Study: NCT01011426
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
Study: NCT02539537
Drug: 5-Fluoro-uracil
Normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01123655
Drug: APLA12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.